New Approach Shows Promise Against KRAS‑Driven Pancreatic Cancer
For many years the KRAS mutation has been regarded as a stubborn obstacle in pancreatic cancer research. It is present in more than nine out of ten tumours, yet its smooth surface offers no obvious pocket for a drug to latch onto, leading scientists to label it undruggable.
Patients with advanced disease have historically faced limited options and poor outcomes. A recent Phase 3 study tested an oral agent called daraxonrasib in people whose pancreatic cancer had progressed after prior therapy. The trial enrolled five hundred participants with metastatic disease.
Those receiving the investigational pill lived a median of 13.2 months, compared with 6.7 months for those given standard chemotherapy. This translates to a roughly sixty percent reduction in the risk of death.
The drug’s mechanism differs from classic direct‑targeting strategies. Daraxonrasib first binds a cellular protein known as cyclophilin A. The resulting complex then attaches to the active form of KRAS and blocks its growth‑promoting signal.
Because it works through this intermediary, the agent can engage multiple active RAS variants simultaneously, which makes it harder for tumour cells to develop a single‑point escape route. Earlier attempts to inhibit KRAS directly failed after cancer cells found work‑arounds.
By contrast, the cyclophilin A‑dependent approach appears to retain activity preserves potency across different KRAS alleles, including the prevalent G12D mutation that drives most pancreatic cancers and is not addressed by the G12C‑focused molecules that emerged after a 2013 breakthrough in lung cancer. Researchers noted that side effects were observed but generally manageable. A skin rash occurred in the majority of participants, while mouth sores, diarrhoea and nausea were also common.
Despite these adverse events, patients on daraxonrasib were less likely to discontinue therapy than those on chemotherapy and reported a better quality of life—a meaningful consideration in a disease where treatment can feel as burdensome as the illness itself. The study’s findings were published in the New England Journal of Medicine.
The compound was developed by Revolution Medicines, which has released the data; regulatory approval has not yet been granted. Experts commenting on the trial describe the result as potentially the most significant advance in pancreatic cancer treatment in a generation, noting that such language is rarely used for this malignancy. Historically, KRAS was identified as an oncogene in the early 1980s and for almost forty years resisted every effort to block it directly.
The protein’s surface lacks the deep crevices that small molecules need to grip, leading to repeated failures. The current results suggest that the long‑standing barrier is beginning to weaken, offering a concrete signal that KRAS can be inhibited in pancreatic cancer with a clinically meaningful effect.
Looking ahead, investigators will need to determine whether the benefit extends to earlier disease stages before tumours have had time to adapt. For now, the trial provides the field with the first clear evidence that targeting KRAS in this setting can produce a survival advantage, pending further regulatory review and real‑world management of side effects.
New Approach Shows Promise Against KRAS‑Driven Pancreatic Cancer
New(1) Approach2 Shows3 Promise4 Against5 KRAS‑Driven6 Pancreatic7 Cancer8
Paragraph1:
For9 many10 years11 the12 KRAS13 mutation14 has15 been16 regarded17 as18 a19 stubborn20 obstacle21 in22 pancreatic23 cancer24 research25.26 It27 is28 present29 in30 more31 than32 nine33 out34 of35 ten36 tumours,37 yet38 its39 smooth40 surface41 offers42 no43 obvious44 pocket45 for46 a47 drug48 to49 latch50 onto,51 leading52 scientists53 to54 label55 it56 undruggable57.58 Patients59 with60 advanced61 disease62 have63 historically64 faced65 limited66 options67 and68 poor69 outcomes70.
Paragraph2:
A71 recent72 Phase 373 study74 tested75 an76 oral77 agent78 called79 daraxonrasib80 in81 people82 whose83 pancreatic84 cancer85 had86 progressed87 after88 prior89 therapy90.91 The92
